Severe Allergic Asthma Treatment in Poland

• Autorzy: Aleksandra Kucharczyk , Joanna Mazurek , Karina Jahnz-Różyk
• Języki publikacji: EN

Abstrakty

EN

Severe asthma is a heterogeneous disease, which, as it is now believed, requires a personalized therapy dependent on phenotype. Omalizumab, a humanized monoclonal antibody that specifically binds to free immunoglobulin E, proved to be particularly effective in the treatment of allergic asthma. Because this treatment is very expensive, in Poland it is reimbursed under the drug program: "Omalizumab treatment of severe, allergic, IgE-dependent asthma". One of the main features of drug programs is precise defining the group of patients, which may be subject to treatment. The current experience shows that it significantly increase the efficacy of the therapy. On the other hand, however, may adversely affect the possibility of treating patients with difficult access to specialized centres.(original abstract)

Słowa kluczowe

EN

Medical treatment; Illness; Medications

PL

Leczenie; Choroby; Leki

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2016
• Numer: nr 2
• Strony: 57--62

Twórcy

autor

Aleksandra Kucharczyk

• Military Institute of Medicine

autor

Joanna Mazurek

• Military Institute of Medicine

autor

Karina Jahnz-Różyk

• Military Institute of Medicine

Bibliografia

• Wenzel S.: Severe asthma: from characteristics to phenotypes to endotypes. Clin. Exp. Allergy. 2012;42:650-658
• Holgate S.T., Chuchalin A.G., Hébert J., Lötvall J., Persson G.B., Chung K.F. et al.: Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 2004; 34(4):632-638.
• Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J. et al.: Benefits of omalizumab as add on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60(3):309-316
• NOTICE OF THE MINISTER OF HEALTH of 26 October 2012 on the list of reimbursed drugs, foodstuffs intended for particular nutritional uses and medical devices at the date of 1 November 2012. Access: http:// www.mz.gov.pl/leki/refundacja/lista-lekow-refundowanych-obwieszczenia-ministra-zdrowia/obwieszczenie-ministra-zdrowia-z-dnia-26-pazdziernika-2012-r
• Annex B.44. to the Notice of the Minister of Health of 28 October 2015 on the list of reimbursed drugs, foodstuffs intended for particular nutritional uses and medical devices at the date of 1 November 2015)
• Bodzenta-Lukaszyk A., Chazan R., Fal A., Kruszewski J., Kuna P., Kupryś-Lipińska I. et al.: Stanowisko Grupy Ekspertów Polskiego Towarzystwa Alergologicznego w sprawie programu terapeutycznego leczenia omalizumabem ciężkiej astmy alergicznej. Alergia Astma Immunol. 2010.15(3):132-133
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. Available from: www.ginasthma.org

Identyfikatory

DOI

10.7365/JHPOR.2016.2.6